AI Engines For more Details: Perplexity Kagi Labs You
Headache: Headache is a common side effect of isosorbide mononitrate therapy, especially when initiating treatment or increasing the dosage. It is usually transient and may improve over time.
Hypotension: Isosorbide mononitrate can cause low blood pressure, leading to symptoms such as dizziness, lightheadedness, and fainting, particularly when standing up quickly from a sitting or lying position.
Tolerance: Prolonged use of isosorbide mononitrate may lead to the development of tolerance, necessitating dose adjustments or medication rotation to maintain its effectiveness in preventing angina.
Reflex Tachycardia: Isosorbide mononitrate-induced vasodilation can trigger reflex tachycardia (rapid heart rate) as the body attempts to compensate for decreased blood pressure. This effect may be more pronounced in individuals with preexisting cardiovascular conditions.
Interaction with Phosphodiesterase-5 Inhibitors: Concurrent use of isosorbide mononitrate with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) or riociguat can potentiate the hypotensive effects and increase the risk of adverse cardiovascular events.
Nitrate Tolerance: Long-term use of nitrates, including isosorbide mononitrate, may lead to the development of nitrate tolerance, requiring intermittent drug-free periods or dose adjustments to maintain efficacy.
Contraindications: Isosorbide mononitrate is contraindicated in individuals with severe hypotension, severe anemia, increased intracranial pressure, or those who have recently taken phosphodiesterase-5 inhibitors or riociguat due to the risk of severe hypotension and cardiovascular collapse.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| ADHD | 0.7 | 0.7 | |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0.1 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
| Allergies | 1 | -1 | |
| Allergy to milk products | 0.5 | 0.1 | 4 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 0.5 | 0.7 | -0.4 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | -0.5 | |
| Ankylosing spondylitis | 0.4 | 0.5 | -0.25 |
| Anorexia Nervosa | 0.1 | 0.5 | -4 |
| Antiphospholipid syndrome (APS) | 0.1 | 0 | 0 |
| Asthma | 0 | 0 | |
| Atherosclerosis | 0.5 | 0 | 0 |
| Atrial fibrillation | 0.7 | 0.2 | 2.5 |
| Autism | 0.9 | 0.8 | 0.13 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| Bipolar Disorder | 0.7 | 0.5 | 0.4 |
| Brain Trauma | 0 | 0 | |
| Carcinoma | 0.7 | 0.6 | 0.17 |
| Celiac Disease | 0.1 | 0.7 | -6 |
| Cerebral Palsy | 0.1 | 0.5 | -4 |
| Chronic Fatigue Syndrome | 1 | 0.4 | 1.5 |
| Chronic Kidney Disease | 0.1 | 0 | 0 |
| Chronic Lyme | 0 | 0 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0 | 0 |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | 0.6 | -2 |
| Colorectal Cancer | 0.7 | 0.7 | |
| Constipation | 0 | 0 | |
| Coronary artery disease | 0.5 | 0.5 | |
| COVID-19 | 0.7 | 1.6 | -1.29 |
| Crohn's Disease | 0.7 | 0.7 | 0 |
| cystic fibrosis | 0 | 0 | |
| deep vein thrombosis | 0.6 | -0.6 | |
| Depression | 1.5 | 1 | 0.5 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.1 | -0.1 | |
| Endometriosis | 0.2 | 0.5 | -1.5 |
| Epilepsy | 0.1 | 0.1 | 0 |
| Fibromyalgia | 0.2 | 0.2 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0 | 0 |
| gallstone disease (gsd) | 0.6 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.1 | 0 | 0 |
| Halitosis | 0.1 | -0.1 | |
| Hashimoto's thyroiditis | 0 | 0 | 0 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0 | 0 | |
| hyperglycemia | 0.1 | -0.1 | |
| hypersomnia | 0 | 0 | |
| hypertension (High Blood Pressure | 0.7 | 0.2 | 2.5 |
| Hypoxia | 0.1 | 0.1 | |
| Inflammatory Bowel Disease | 0.1 | 1.8 | -17 |
| Insomnia | 0.1 | 0 | 0 |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 0.5 | 0.2 | 1.5 |
| Liver Cirrhosis | 0.8 | 0.6 | 0.33 |
| Long COVID | 0.4 | 1.7 | -3.25 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.5 | -0.5 | |
| ME/CFS with IBS | 0.2 | 0.2 | |
| ME/CFS without IBS | 0.2 | 0.3 | -0.5 |
| Metabolic Syndrome | 0.8 | 0.9 | -0.13 |
| Mood Disorders | 2 | 1 | 1 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.9 | 1 | -0.11 |
| Multiple system atrophy (MSA) | 0.2 | 0.5 | -1.5 |
| Neuropathy (all types) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.5 | -4 |
| Obesity | 0.9 | 0.9 | 0 |
| obsessive-compulsive disorder | 1.2 | 1.2 | |
| Osteoarthritis | 0.1 | 0.5 | -4 |
| Osteoporosis | 0.5 | 0.5 | |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.2 | 0.6 | -2 |
| Polycystic ovary syndrome | 0.6 | 1 | -0.67 |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| Psoriasis | 0.6 | 0.5 | 0.2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 0 | 0 |
| Rosacea | 0.5 | 0 | 0 |
| Schizophrenia | 0.7 | 0.5 | 0.4 |
| scoliosis | 0.5 | -0.5 | |
| Sjögren syndrome | 0.2 | 0.1 | 1 |
| Sleep Apnea | 0.5 | 0 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.2 | 0 | 0 |
| Systemic Lupus Erythematosus | 0.2 | 0.5 | -1.5 |
| Tic Disorder | 0.5 | 0.5 | |
| Type 1 Diabetes | 0.5 | 0.1 | 4 |
| Type 2 Diabetes | 0.8 | 0.7 | 0.14 |
| Ulcerative colitis | 0.2 | 0.2 | 0 |
| Unhealthy Ageing | 0.3 | 0 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.